On July 21, 2026, the clinical trial registry recorded an update for a study involving ipamorelin. The trial, titled the Trifecta Research Study, is registered under identifier NCT07717866. Its current status is listed as active, not recruiting. No phase designation was provided in the available data.
An active, not recruiting status indicates that the study is ongoing but is no longer enrolling new participants. This update does not include any information about trial results, outcomes, or findings. No efficacy or safety data were disclosed as part of this status change.
Ipamorelin remains classified as an unapproved compound intended for research purposes only. This trial update is a procedural status change and should not be interpreted as an indication of the study's eventual outcome or conclusions.
Interested readers can consult the official clinical trial registry listing for the most current and detailed information regarding the Trifecta Research Study, including any future updates on enrollment status, phase details, or results as they become available. For additional context on this compound, readers are encouraged to consult the compound overview.